Tags

Type your tag names separated by a space and hit enter

Review of serologic testing for hepatitis C virus infection and risk of posttransfusion hepatitis C.
Arch Pathol Lab Med 1994; 118(4):342-5AP

Abstract

Hepatitis C virus (HCV) is a major cause of acute and chronic hepatitis and cirrhosis worldwide. Screening volunteer donors for antibody to HCV (anti-HCV) has reduced the risk of posttransfusion hepatitis C to less than 1.0% per recipient. Virtually all persons with acute HCV infection seem to become chronically infected, and an average of 67% acquire chronic liver disease with persistently elevated liver enzyme values. Among anti-HCV-positive blood donors, 70% to 90% are HCV RNA positive, but less than half have biochemical evidence of liver disease. The extraordinarily high rate of persistent infection observed in humans and the lack of protection against rechallenge with homologous HCV strains demonstrated in experimental studies in chimpanzees suggest that HCV fails to induce an effective neutralizing antibody response. This raises major concerns for the development of effective passive or active immunoprophylaxis against hepatitis C.

Authors+Show Affiliations

Hepatitis Branch, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

7513149

Citation

Alter, M J.. "Review of Serologic Testing for Hepatitis C Virus Infection and Risk of Posttransfusion Hepatitis C." Archives of Pathology & Laboratory Medicine, vol. 118, no. 4, 1994, pp. 342-5.
Alter MJ. Review of serologic testing for hepatitis C virus infection and risk of posttransfusion hepatitis C. Arch Pathol Lab Med. 1994;118(4):342-5.
Alter, M. J. (1994). Review of serologic testing for hepatitis C virus infection and risk of posttransfusion hepatitis C. Archives of Pathology & Laboratory Medicine, 118(4), pp. 342-5.
Alter MJ. Review of Serologic Testing for Hepatitis C Virus Infection and Risk of Posttransfusion Hepatitis C. Arch Pathol Lab Med. 1994;118(4):342-5. PubMed PMID: 7513149.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Review of serologic testing for hepatitis C virus infection and risk of posttransfusion hepatitis C. A1 - Alter,M J, PY - 1994/4/1/pubmed PY - 1994/4/1/medline PY - 1994/4/1/entrez SP - 342 EP - 5 JF - Archives of pathology & laboratory medicine JO - Arch. Pathol. Lab. Med. VL - 118 IS - 4 N2 - Hepatitis C virus (HCV) is a major cause of acute and chronic hepatitis and cirrhosis worldwide. Screening volunteer donors for antibody to HCV (anti-HCV) has reduced the risk of posttransfusion hepatitis C to less than 1.0% per recipient. Virtually all persons with acute HCV infection seem to become chronically infected, and an average of 67% acquire chronic liver disease with persistently elevated liver enzyme values. Among anti-HCV-positive blood donors, 70% to 90% are HCV RNA positive, but less than half have biochemical evidence of liver disease. The extraordinarily high rate of persistent infection observed in humans and the lack of protection against rechallenge with homologous HCV strains demonstrated in experimental studies in chimpanzees suggest that HCV fails to induce an effective neutralizing antibody response. This raises major concerns for the development of effective passive or active immunoprophylaxis against hepatitis C. SN - 0003-9985 UR - https://www.unboundmedicine.com/medline/citation/7513149/Review_of_serologic_testing_for_hepatitis_C_virus_infection_and_risk_of_posttransfusion_hepatitis_C_ L2 - http://www.diseaseinfosearch.org/result/3332 DB - PRIME DP - Unbound Medicine ER -